Felix T. Garzon

550 total citations
12 papers, 445 citations indexed

About

Felix T. Garzon is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Felix T. Garzon has authored 12 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 4 papers in Hematology and 3 papers in Molecular Biology. Recurrent topics in Felix T. Garzon's work include Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Metal complexes synthesis and properties (3 papers). Felix T. Garzon is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Metal complexes synthesis and properties (3 papers). Felix T. Garzon collaborates with scholars based in Germany, United States and France. Felix T. Garzon's co-authors include Martin R. Berger, Bernhard K. Keppler, D. Schmähl, Ulrich A. Simanowski, Matthias Maiwald, Martin Berger, Timothy J. Peters, Armin Koch, Helmut K. Seitz and J.M. Rideout and has published in prestigious journals such as Blood, Gastroenterology and Cancer Letters.

In The Last Decade

Felix T. Garzon

12 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felix T. Garzon Germany 8 154 133 128 92 79 12 445
Julie Fuller United States 8 137 0.9× 113 0.8× 129 1.0× 42 0.5× 32 0.4× 19 538
Carol A. Cucchi United States 11 310 2.0× 92 0.7× 445 3.5× 69 0.8× 84 1.1× 15 734
Aglair B. Garcia Brazil 15 144 0.9× 56 0.4× 212 1.7× 26 0.3× 189 2.4× 30 545
Kristell Marzin Germany 11 196 1.3× 47 0.4× 169 1.3× 55 0.6× 52 0.7× 18 545
Claudia Dallinger Germany 8 115 0.7× 75 0.6× 156 1.2× 96 1.0× 18 0.2× 10 582
KR Harrap United Kingdom 11 355 2.3× 127 1.0× 252 2.0× 104 1.1× 41 0.5× 21 602
Masanori Umeda Japan 15 145 0.9× 139 1.0× 275 2.1× 46 0.5× 113 1.4× 59 533
Krakoff Ih United States 13 198 1.3× 87 0.7× 156 1.2× 53 0.6× 50 0.6× 24 440
C. Van Der Heul Netherlands 14 42 0.3× 56 0.4× 345 2.7× 76 0.8× 198 2.5× 29 698
Linda Hogarth United Kingdom 14 152 1.0× 48 0.4× 387 3.0× 31 0.3× 91 1.2× 29 666

Countries citing papers authored by Felix T. Garzon

Since Specialization
Citations

This map shows the geographic impact of Felix T. Garzon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix T. Garzon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix T. Garzon more than expected).

Fields of papers citing papers by Felix T. Garzon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix T. Garzon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix T. Garzon. The network helps show where Felix T. Garzon may publish in the future.

Co-authorship network of co-authors of Felix T. Garzon

This figure shows the co-authorship network connecting the top 25 collaborators of Felix T. Garzon. A scholar is included among the top collaborators of Felix T. Garzon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix T. Garzon. Felix T. Garzon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Treon, Steven P., Christian Buske, Sheeba K. Thomas, et al.. (2021). Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood. 138(Supplement 1). 1362–1362. 11 indexed citations
2.
3.
4.
Guilhot, François, Jane F. Apperley, Dong-Wook Kim, et al.. (2007). Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).. Blood. 110(11). 470–470. 22 indexed citations
5.
6.
Seitz, Helmut K., Ulrich A. Simanowski, Felix T. Garzon, et al.. (1990). Possible role of acetaldehyde in ethanol-related rectal cocarcinogenesis in the rat. Gastroenterology. 98(2). 406–413. 189 indexed citations
7.
Berger, Martin R., Felix T. Garzon, Bernhard K. Keppler, & D. Schmähl. (1989). Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats.. PubMed. 9(3). 761–5. 69 indexed citations
8.
Garzon, Felix T., et al.. (1988). Technique for long-term infusion into the inferior mesenteric artery of unrestrained rats. Laboratory Animals. 22(2). 173–176. 2 indexed citations
9.
Garzon, Felix T., Martin R. Berger, Bernhard K. Keppler, & D. Schm�hl. (1987). Comparative antitumor activity of ruthenium derivatives with 5?-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats. Cancer Chemotherapy and Pharmacology. 19(4). 347–9. 42 indexed citations
10.
Berger, Martin R., Barbara Schüler, H. R. Scherf, et al.. (1987). Alkyl phosphocholines: Toxicity and anticancer properties. Lipids. 22(11). 930–934. 57 indexed citations
11.
Garzon, Felix T., Martin R. Berger, Bernhard K. Keppler, & D. Schmähl. (1987). Paradoxical effect of dichlorobis(1-phenylbutane-1,3-dionato)molybdenum (IV), (Mo(bzac)2Cl2 on the growth of autochthonous chemically induced colorectal tumors in SD rats. Cancer Letters. 34(3). 325–330. 4 indexed citations
12.
Garzon, Felix T., M. Salas, Martin R. Berger, & Holger Kirchner. (1986). Effect of interleukin-2 on the manifestation and growth of acetoxymethyl-methylnitrosamine-induced colorectal rat adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 111(1). 79–81. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Fuller Breakdown of academic impact, for papers by Carol A. Cucchi Breakdown of academic impact, for papers by Aglair B. Garcia Breakdown of academic impact, for papers by Kristell Marzin Breakdown of academic impact, for papers by Claudia Dallinger Breakdown of academic impact, for papers by KR Harrap Breakdown of academic impact, for papers by Masanori Umeda Breakdown of academic impact, for papers by Krakoff Ih Breakdown of academic impact, for papers by C. Van Der Heul Breakdown of academic impact, for papers by Linda Hogarth
Rankless by CCL
2026